LOGO
LOGO

RxSight Sets Sights On 32% To 41% Revenue Growth In 2025

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024 lt

RxSight Inc. (RXST), an ophthalmic medical device company, which reported an impressive 57% year-over-year revenue growth in 2024, is projecting continued success in 2025.

The company markets its proprietary, FDA-approved RxSight Light Adjustable Lens (LAL) system, which is designed to enhance the outcomes of post-cataract surgery patients. The LAL system includes the Light Adjustable Lens (LAL), the Light Delivery Device (LDD), and a range of essential accessories.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.